Akebia Therapeutics (AKBA) Net Income Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Net Income Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 68.18% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -0.17% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -384.49% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -14.68% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 105.80% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 2,405.06% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -14.93% |
| 10 | Akebia Therapeutics | 339.15 Mn | 176.55 Mn | 41.25 Mn | -248.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -248.13% |
| Dec 31, 2025 | 46.31% |
| Sep 30, 2025 | 102.69% |
| Jun 30, 2025 | 102.88% |
| Mar 31, 2025 | 133.98% |
| Dec 31, 2024 | -3,814.01% |
| Sep 30, 2024 | -38.30% |
| Jun 30, 2024 | 23.18% |
| Mar 31, 2024 | 33.08% |
| Dec 31, 2023 | 114.89% |
| Sep 30, 2023 | 72.40% |
| Jun 30, 2023 | -135.61% |
| Mar 31, 2023 | 56.85% |
| Dec 31, 2022 | 93.95% |
| Sep 30, 2022 | 8.82% |
| Jun 30, 2022 | 138.24% |
| Mar 31, 2022 | 7.92% |
| Dec 31, 2021 | 22.91% |
| Sep 30, 2021 | 3.96% |
| Jun 30, 2021 | 53.32% |